Marcia Belvin

12.7k citations

74 papers · 6.9k indexed · 5 hit papers · h-index 37

Molecular Biology top 2%
Immunology top 0.5%
Oncology top 1%
Insect Science top 0.5%
Cellular and Molecular Neuroscience top 2%

Co-authors: Kathryn V. Anderson Lori S. Friedman Dominique Ferrandon Vanessa Gobert Marie Gottar Jules A. Hoffmann Julien Royet Klaus P. Hoeflich
Topics: PI3K/AKT/mTOR signaling in cancer (21 papers)Melanoma and MAPK Pathways (19 papers)Monoclonal and Polyclonal Antibodies Research (8 papers)
Cited by: Immunology Insect Science Oncology
Journals: Nature Science Cell
Partner nations: United States France United Kingdom

In The Last Decade

Marcia Belvin

74 papers receiving 6.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A CONSERVED SIGNALING PATHWAY: The Drosophila Toll-Dorsal Pathway

1996 666 citations Marcia Belvin, Kathryn V. Anderson profile →
The Drosophila immune response against Gram-negative bacteria is mediated by a peptidoglycan recognition protein

2002 554 citations Marie Gottar, Vanessa Gobert et al. profile →
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

2016 527 citations Peter Ebert, Jeanne Cheung et al. Immunity profile →
Dual Detection of Fungal Infections in Drosophila via Recognition of Glucans and Sensing of Virulence Factors

2006 357 citations Marie Gottar, Vanessa Gobert et al. Cell profile →
A genome-wide analysis of immune responses in Drosophila

2001 328 citations Marcia Belvin, Casey Kopczynski et al. profile →

Peers

Countries citing papers authored by Marcia Belvin

Since Specialization

Citations

This map shows the geographic impact of Marcia Belvin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcia Belvin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcia Belvin more than expected).

Fields of papers citing papers by Marcia Belvin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcia Belvin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcia Belvin. The network helps show where Marcia Belvin may publish in the future.

Co-authorship network of co-authors of Marcia Belvin

This figure shows the co-authorship network connecting the top 25 collaborators of Marcia Belvin. A scholar is included among the top collaborators of Marcia Belvin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcia Belvin. Marcia Belvin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity 2022 ·Cancer Research ·Leila M. Boustany,Sherry L. LaPorte,(unknown),(unknown),(unknown),Joel Shen,(unknown),(unknown),Michael B. Winter,Stephen J. Moore,Mei Li,Linnea Diep,Yuanhui Huang,Shouchun Liu,Olga Vasiljeva,Jim West,Jennifer Richardson,Bryan Irving,Marcia Belvin,W. Michael Kavanaugh	35
2	Role of the E3 ubiquitin ligase RNF157 as a novel downstream effector linking PI3K and MAPK signaling pathways to the cell cycle 2017 ·Journal of Biological Chemistry ·Taner Dogan,Florian Gnad,Jocelyn Chan,Lilian Phu,Amy Young,Jinan Chen,Sophia Doll,Matthew P. Stokes,Marcia Belvin,Lori S. Friedman,Donald S. Kirkpatrick,Klaus P. Hoeflich,Georgia Hatzivassiliou	19
3	MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockadebreakdown → 2016 ·Immunity ·Peter Ebert,Jeanne Cheung,Yagai Yang,Erin McNamara,Rebecca Hong,Марина Москаленко,Stephen E. Gould,Heather Maecker,Bryan Irving,Jeong Kim,Marcia Belvin,Ira Mellman	527
4	GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo 2012 ·Clinical Cancer Research ·Jeffrey J. Wallin,Jane Guan,Wei Wei Prior,Leslie B. Lee,Leanne Berry,Lisa D. Belmont,Hartmut Koeppen,Marcia Belvin,Lori S. Friedman,Deepak Sampath	73
5	An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer 2012 ·Cancer Research ·Mark L. McCleland,Adam S. Adler,Yonglei Shang,Thomas Hunsaker,Tom Truong,David Peterson,Eric Torres,(unknown),Benjamin Haley,Jean-Philippe Stéphan,Marcia Belvin,Georgia Hatzivassiliou,Elizabeth M. Blackwood,Laura Corson,Marie Evangelista,Jiping Zha,Ron Firestein	150
6	Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor 2012 ·Clinical Cancer Research ·Harvey Wong,Laurent Vernillet,Amy Peterson,Joseph A. Ware,Lillian Lee,Jean‐François Martini,Peiwen Yu,Congfen Li,Geoffrey Del Rosario,Edna F. Choo,Klaus P. Hoeflich,Yongchang Shi,Blake T. Aftab,(unknown),(unknown),Marcia Belvin,John Prescott	65
7	ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors 2012 ·Molecular Cancer Therapeutics ·Georgia Hatzivassiliou,Bonnie Liu,Carol O’Brien,Jill M. Spoerke,Klaus P. Hoeflich,Peter M. Haverty,Robert Soriano,William F. Forrest,Sherry Heldens,Huifen Chen,Karen Toy,Connie Ha,Wei Zhou,Kyung Song,Lori S. Friedman,Lukas C. Amler,Garret M. Hampton,John G. Moffat,Marcia Belvin,Mark R. Lackner	155
8	mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations 2012 ·Cancer Letters ·Ulka Vijapurkar,Liliane Robillard,(unknown),Michael Degtyarev,Kwang‐Huei Lin,Tom Truong,Jarrod R. Tremayne,Leanne Ross,Zhonghua Pei,Lori S. Friedman,Elizabeth M. Blackwood,Marcia Belvin	6
9	PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts 2012 ·Cancer Chemotherapy and Pharmacology ·Edna F. Choo,Chee M. Ng,Leanne Berry,Marcia Belvin,Nicholas Lewin‐Koh,Mark Merchant,Laurent Salphati	26
10	Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition 2011 ·Cancer Research ·Klaus P. Hoeflich,Mark Merchant,Christine Orr,Jocelyn Chan,(unknown),Leanne Berry,Ian Kasman,Hartmut Koeppen,(unknown),Nai-Ying Yang,Stefan Engst,Stuart H. Johnston,Lori S. Friedman,Marcia Belvin	200
11	Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors 2010 ·Cancer Research ·Kyle A. Edgar,Jeffrey J. Wallin,Megan Berry,Leslie B. Lee,Wei Wei Prior,Deepak Sampath,Lori S. Friedman,Marcia Belvin	94
12	Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor 2010 ·Xenobiotica ·Edna F. Choo,Marcia Belvin,Jocelyn Chan,Klaus P. Hoeflich,Christine Orr,Kirk Robarge,Xiaoye Yang,Mark Zak,Jason Boggs	17
13	In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models 2009 ·Clinical Cancer Research ·Klaus P. Hoeflich,Carol O’Brien,Zachary Boyd,Guy Cavet,Steve Guerrero,Kenneth Jung,Tom Januario,Heidi Savage,Elizabeth A. Punnoose,Tom Truong,Wei Zhou,Leanne Berry,Lesley Murray,Lukas C. Amler,Marcia Belvin,Lori S. Friedman,Mark R. Lackner	385
14	Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression 2009 ·Cancer Research ·Klaus P. Hoeflich,Sylvia Herter,Janet Tien,Leo Lap-Yan Wong,Leanne Berry,Jocelyn Chan,Carol O’Brien,Zora Modrušan,Somasekar Seshagiri,Mark R. Lackner,Howard M. Stern,Edna F. Choo,Lesley Murray,Lori S. Friedman,Marcia Belvin	144
15	Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab 2009 ·Clinical Cancer Research ·Evelyn Yao,Wei Zhou,Si Tuen Lee-Hoeflich,Tom Truong,Peter M. Haverty,Jeffrey Eastham‐Anderson,Nicholas Lewin‐Koh,Bert Gunter,Marcia Belvin,Lesley Murray,Lori S. Friedman,Mark X. Sliwkowski,Klaus P. Hoeflich	104
16	Dual Detection of Fungal Infections in Drosophila via Recognition of Glucans and Sensing of Virulence Factorsbreakdown → 2006 ·Cell ·Marie Gottar,Vanessa Gobert,Alexey A. Matskevich,Jean‐Marc Reichhart,Chengshu Wang,Tariq M. Butt,Marcia Belvin,Jules A. Hoffmann,Dominique Ferrandon	357
17	The Drosophila Immune Defense against Gram-Negative Infection Requires the Death Protein dFADD 2002 ·Immunity ·Silvia Naitza,Carine Rossé,Christine Kappler,Philippe Georgel,Marcia Belvin,David Gubb,Jacques Camonis,Jules A. Hoffmann,Jean-Marc Reichhart	126
18	fusilli, an Essential Gene with a Maternal Role in Drosophila Embryonic Dorsal–Ventral Patterning 2001 ·Developmental Biology ·(unknown),Marcia Belvin,(unknown),Kathryn V. Anderson	16
19	Drosophila p53 Is a Structural and Functional Homolog of the Tumor Suppressor p53 2000 ·Cell ·Michael Ollmann,Lynn Young,Charles J. Di Como,Felix Karim,Marcia Belvin,Stephanie Robertson,Kellie Whittaker,(unknown),William W. Fisher,Andrew R. Buchman,Geoffrey M. Duyk,Lori S. Friedman,Carol Prives,Casey Kopczynski	336
20	Drosophila learning and memory: Recent progress and new approaches 1997 ·BioEssays ·Marcia Belvin,Jerry C.P. Yin	20

About Marcia Belvin

Marcia Belvin is a scholar working on Oncology, Molecular Biology and Immunology, having authored 74 papers that have together received 6.9k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (21 papers), Melanoma and MAPK Pathways (19 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). The work is most often cited by research in Immunology (2.8k citations), Insect Science (1.3k citations) and Oncology (2.0k citations). Marcia Belvin has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Kathryn V. Anderson, Lori S. Friedman, Dominique Ferrandon, Vanessa Gobert, Marie Gottar, Jules A. Hoffmann, Julien Royet, Klaus P. Hoeflich, Geoffrey M. Duyk and Jean‐Marc Reichhart. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact